Disclaimer to the Online Edition
This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.
metroNIDAZOLE
Indication
- Treatment of documented or suspected infections caused by susceptible anaerobic bacteria and protozoa such as Bacteroides fragilis, Trichomonas vagilis, Entamoeba histolytica, Giardia lambia, or Clostridiodes species
- Necrotizing enterocolitis complicated by intestinal perforation
Dosage Guidelines
Postnatal Age | Weight (kg) | Dose |
Any | Less than 1.2 | 7.5 mg/kg/dose IV q48h |
0 to 7 days | 1.2 to 2 | 7.5 mg/kg/dose IV q24h |
Greater than 2 | 7.5 mg/kg/dose IV q12h | |
Greater than 7 days | 1.2 to 2 | 7.5 mg/kg/dose IV q12h |
Greater than 2 | 15 mg/kg/dose IV q12h |
Administration
- IV intermittent slow infusion over 30 minutes
Adverse Effects
- Diarrhea, vomiting, rash, neutropenia, thrombophlebitis
Comments
- Monitor CBC at baseline
- In severe renal impairment reduce dose by 50%
- May in rare cases colour urine dark red/brown
Supplied As
- 500 mg/100 mL IV minibag
- 5 mg/mL patient specific syringe, prepared by Pharmacy